Summary:
In adults with overweight or obesity participating in the STEP 1-4 Phase 3a trials over 68 weeks, once-weekly semaglutide 2.4 mg combined with lifestyle interventions significantly improved physical functioning and weight-related quality of life (WRQOL), with 51.8% meeting meaningful improvement thresholds compared to 28.3% on placebo (p<0.0001), compared to weekly placebo combined with lifestyle interventions. Health-related quality of life (HRQOL) improvements were noted, but some domains (e.g., SF-36v2 Role Emotional in STEP 2) showed no significant changes.
| PICO | Description |
|---|---|
| Population | Adults with overweight or obesity participating in the STEP 1-4 Phase 3a trials, assessed over a 68-week period. |
| Intervention | Once-weekly administration of semaglutide 2.4 mg, combined with lifestyle interventions for weight management and improving quality of life. |
| Comparison | Weekly administration of a placebo, combined with lifestyle interventions for weight management, across the same trial period. |
| Outcome | Semaglutide 2.4 mg demonstrated significant improvements in physical functioning and weight-related quality of life (WRQOL) versus placebo. Results included higher scores on IWQOL-Lite-CT and SF-36v2 scales, with greater proportions achieving meaningful within-person changes. For example, in STEP 1, 51.8% of participants on semaglutide met improvement thresholds compared to 28.3% on placebo (p<0.0001). Improvements were also observed in health-related quality of life (HRQOL), though some domains, like SF-36v2 Role Emotional in STEP 2, showed no significant changes. |
Source: Rubino, Domenica, et al. “Effect of Semaglutide 2.4 mg on Physical Functioning and Weight- and Health-Related Quality of Life in Adults with Overweight or Obesity: Patient-Reported Outcomes from the STEP 1-4 Trials.” Diabetes, Obesity and Metabolism. Read article here.
